Sample Manager was developed to be a user-friendly and efficient application for the management of samples and their data.

LabKey Sample Manager has been designed with an intuitive user interface providing a gateway to powerful features that address common challenges in laboratory sample management.

SEATTLE (PRWEB)
February 05, 2020

LabKey has released Sample Manager, sample management software developed to bring greater ease, efficiency and insight to sample processing within laboratories.

Built with input from a Product Advisory Council (PAC) comprised of academic and biotech laboratories conducting research in various fields, LabKey Sample Manager has been designed with an intuitive user interface providing a gateway to powerful features that address common challenges in laboratory sample management. These features include user-friendly mechanisms to create samples within the application and discern sample lineage, workflow features to easily assign and track sample processing tasks, and data integration features to unify samples with their related experiment data. When consulting with the Sample Manager PAC, these features were deemed essential to the application due to their ability to boost sample processing efficiency, operational control and data integrity.

“Having participated in the Sample Manager PAC and seeing the development of the application from idea to fruition, Sample Manager has been thoughtfully developed and has the potential to positively impact the collaboration, efficiency and throughput of many laboratories” says Mike MacCoss, Professor of Genome Sciences at the University of Washington. “Additionally, the ability to tie experiment data directly to samples within the application is a real benefit when trying to get a big picture view of the ongoing work taking place in the lab.”

Sample Manager is initially targeted at small to medium sized labs with plans to expand functionality to meet the needs of larger enterprise level organizations. It is available as a stand alone application or included with the Premium Editions of LabKey Server – a data integration, workflow and collaboration platform built for scientific researchers. For more information on LabKey Sample Manager visit please visit LabKey.com.

About LabKey – Since 2003, LabKey has provided software solutions that help overcome the data management, collaboration and workflow challenges faced by scientific research teams worldwide. Serving more than 500 research organizations and thousands of users, LabKey works hand-in-hand with clients to understand the complex needs of modern labs and develop solutions that help bridge the gap from data to discovery. To learn more visit http://www.labkey.com.

Share article on social media or email:

FARMINGTON, Conn. (PRWEB)
February 04, 2020

Shoreline Biome, a microbiome research company that develops tools for characterizing microbiome populations down to the strain level, has announced a new distribution partnership in Asia.

The distribution partner, Gene Company Limited, will sell Shoreline Biome’s microbiome kits and other products to companies and research organizations in China, Hong Kong, and Macau.

Gene Company Limited is a professional life science instrument and reagent supplier serving China and nearby regions. The company was established in Hong Kong in 1992.

“Distribution agreements such as these enable researchers outside the U.S. to access our transformative tools and technologies to comprehensively study all bacteria in microbiome samples,” said Bill McKenzie, Shoreline Biome’s CEO. “Our all-in-one kits and software accelerate breakthroughs in microbiome research by streamlining workflows and reducing time to result.”

According to Zion Market Research, the Asia Pacific region—notably China—is expected to see the highest growth globally in human microbiome research between now and 2024.

A detailed list of Shoreline Biome’s international distributors and ordering information by country can be accessed at shorelinebiome.com/international-distributors.

For more information about Gene Company Limited, visit genecompany.com.

About Shoreline Biome:

Characterizing the human microbiome and analyzing its role in human health and disease are priority goals for researchers around the world. Shoreline Biome accelerates breakthroughs in microbiome research by developing transformative discovery tools that characterize microbiome populations down to the strain level. With Shoreline Biome products, all it takes is three easy steps: lyse, purify, and amplify. Shoreline Biome’s easy-to-use companion analysis software and comprehensive reference database enables straightforward strain-level identification and quantitation of all bacteria in the sample. To learn more, visit shorelinebiome.com.

Share article on social media or email:

Today’s test menus cannot be static. Infections appear or they enter markets they are not expected in. Even large panels with scores of tests won’t cover everything.

ARLINGTON, Va. (PRWEB)
January 30, 2020

The recent novel coronavirus, responsible for over 100 deaths in the Hubei province in China at the time of writing, undermines any notion of a known quantity of infectious disease threats in the world that lab analyzer menus will remain adequate, according to IVD market research Kalorama Information. Swine flu, Ebola, and Zika were reminders that laboratories need to be vigilant and that in vitro diagnostic test makers must constantly update assays that providers can use to identify threats.

“Today’s test menus cannot be static,” said Bruce Carlson, publisher of Kalorama Information. “Infections appear or they enter markets they are not expected in. Even large panels with scores of tests won’t cover everything.”

Diagnostic tools such as reverse transcription polymerase chain reaction (RT-PCR) and sequencers have been used in characterizing and identifying the virus, and new tests are in development. IVD vendors are supporting efforts. Meridian Bioscience announced that its freeze-dried Lyo-Ready 1-Step RT q-PCR mix is being used in the coronavirus outbreak in China.

Kalorama Information projects the infectious disease IVD testing market to be worth more than $18 billion, according to its latest complete world infectious disease market research report, with revenue growth higher than the 4% of normal testing markets.

The new virus — dubbed 2019-nCoV — has already been sequenced, and Chinese health authorities have posted the full genome via the Global Initiative on Sharing All Influenza Data (GISAID) portal, which collects information on respiratory diseases. This allowed other researchers to quickly detect the RNA mechanisms of the virus and develop novel detection methods. Using this information, the U.S. Centers for Disease Control and Prevention (CDC) has developed its own real-time PCR test.

Study of the genetic code revealed that the novel betacoronavirus is in the same virus family as severe acute respiratory syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV); in those diseases, bats were the source. The name coronavirus comes from the virus’ crown-shaped appearance when viewed in electron microscopy, and, indeed, the shape appears to be a significant detail. It is believed that the heavily glycosylated “spike” protein helps it fuse with host cell membranes, assisting the virus to spread to host cells.

At the time of writing, the CDC laboratory in Atlanta was the only U.S. lab indicated to complete viral isolation and perform real-time PCR to diagnose 2019-nCoV; however, the agency has distributed test protocols and plans to make reagents available. For cases of suspected coronavirus in patients having recently traveled to affected regions, the CDC procedures call for the collection of sputum, nasopharyngeal swabs, and blood.

Currently, no testing kits specifically for 2019-nCoV are commercially available. On January 23, Altona Diagnostics announced it was in the process of developing a molecular diagnostic assay for detecting 2019-nCoV in close cooperation with major reference institutes for emerging diseases. Altona Diagnostics was one of the first companies to make reliable molecular diagnostic kits commercially available during outbreaks of SARS-CoV, MERS-CoV, and the Ebola and Zika viruses, among others.

Also, molecular diagnostics maker Co-Diagnostics announced several days ago that it has completed design work for a PCR screening test for the new virus.

If experiences with the Ebola and Zika viruses are any indication, IVD vendors will be at work modifying test technologies and developing tests for emergency approval.

Roche and Chembio Diagnostic Systems were among the vendors to produce emergency use authorization (EUA) tests for Ebola. A number of coronavirus MERS tests are on the market — including Siemens Fast Track, Seegene Anyplex, Roche LightMix, and Bio-Rad CFX96 — and the manufacturers are in a good position to adapt their technology for related novel viruses. Abbott Laboratories indicated that it is actively monitoring the 2019-nCoV outbreak in a recent podcast.

Kalorama Information’s Infectious Disease Diagnostics World Market Analysis: HIV/AIDS, Hepatitis, Tuberculosis, STDs, HAIs, ID/AST, Influenza, TORCH, Other report contains market sizing for every major country market in the world. https://kaloramainformation.com/product/infectious-disease-diagnostics-world-market-analysis/

Data provided include the following:

• 
  Global Infectious Disease IVD Demand by Country/Region 2018 – 2026 (million dollars) (North America: United States, Canada & Mexico; Western Europe; Asia/Pacific: China, Japan, Other; Cent & So America; Eastern Europe; Middle East; Africa; Total World)
• North America – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total N Amer)
• United States – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total US)
• Canada – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Canada)
• Mexico – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Mexico)
• Western Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total W. Europe)
• Germany – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Germany)
• France – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total France)
• United Kingdom – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total UK)
• Italy – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Italy)
• Spain – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Spain)
• Other Western Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total OWE)
• Other Western Europe – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Netherlands, Belgium, Austria, Sweden, Switzerland, Denmark, Portugal, Norway, Greece, Ireland, Finland, All Other)
• Asia/Pacific – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Asia/Pacific)
• China – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total China)
• Japan – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Japan)
• India – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total India)
• South Korea – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total South Korea)
• Australia – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Australia)
• Other Asia/Pacific – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Other Asia/Pacific)
• Other Asia/Pacific – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Indonesia, Taiwan, Thailand, Philippines, Vietnam, Malaysia, Pakistan, Hong Kong, Singapore, New Zealand, All Other)
• Central & South America – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total C & S Amer)
• Brazil – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Brazil)
• Other Central & South America – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Other Cent & So Amer)
• Other Central & South America – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Argentina, Colombia, Chile, Peru, Venezuela, All Other)
• Eastern Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total E Europe)
• Russia – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Russia)
• Other Eastern Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Other E. Europe)
• Other Eastern Europe – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Poland, Romania, Czechia, Ukraine, Hungary, All Other)
• Middle East – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Middle East)
• Turkey – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Turkey)
• Other Middle East – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Other Middle East)
• Other Middle East – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Iran, Saudi Arabia, Iraq, Israel, UAE, All Other)
• Africa – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Africa)
• Africa – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Egypt, South Africa, Nigeria, All Other)

About Kalorama Information

For more than 30 years, Kalorama Information has been a leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), imaging, biotechnology, healthcare, medical devices, and pharmaceuticals.

Share article on social media or email:

“Professor Quintana collaborates on a global scale to apply creative approaches to very complex questions about what triggers brain inflammation in multiple sclerosis and to find ways to stop it,” said Bruce Bebo, Ph.D.,National MS Society.

NEW YORK (PRWEB)
January 28, 2020

Francisco J. Quintana, Ph.D., a leading multiple sclerosis researcher at the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, Harvard Medical School, is the winner of the 2019 Barancik Prize for Innovation in MS Research.

Quintana has established innovative research programs that use advanced technology to make significant contributions to the understanding of the immune response and to identify potential therapeutic targets and biomarkers for MS. He recently developed a new research platform to identify gene-environment interactions that control central nervous system inflammation that drives the damage that occurs in MS. The studies identified novel pathways involved in the regulation of this inflammation. Moreover, these studies map out a novel way to systematically investigate environmental factors in MS and other diseases.

“I am deeply honored to be selected for the Barancik Prize, and thank the Award Committee for recognizing our work,” said Quintana.

“Professor Quintana collaborates on a global scale to apply creative approaches to very complex questions about what triggers brain inflammation in multiple sclerosis and to find ways to stop it,” said Bruce Bebo, Ph.D., executive vice president at the National MS Society, which administers the award. “He has earned the Barancik Prize for being highly resourceful in applying advanced technologies to make progress toward developing new treatment approaches, especially for progressive forms of MS.”

Quintana earned a diploma in biology from the University of Buenos Aires and adoctorate in immunology from the Weizmann Institute of Science in Rehovot, Israel. He completed his postdoctoral training at the Weizmann Institute and at Brigham and Women’s Hospital. He is a Professor of Neurology at the Ann Romney Center for Neurologic Diseases, an Associate Member at the Broad Institute of Harvard and MIT, and incoming president of the International Society of Neuroimmunology. His awards are numerous, including Young Investigator Awards in Ireland and Italy, a Pathway to Independence Award from NIAID/NIH, and recipient of a National MS Society Harry Weaver Scholar Award. He has trained more than 30 young investigators, and participates in several programs focused on training scientists from underrepresented minorities.

Quintana will receive the award and deliver the Barancik Prize lecture at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum on Feb. 27 in West Palm Beach, Florida.

About the Barancik Prize for Innovation in MS Research

The Barancik Prize seeks to recognize and encourage exceptional innovation and originality in scientific research relevant to multiple sclerosis, with emphasis on impact and potential of the research to lead to pathways for the treatment and cure for MS, and scientific accomplishments that merit recognition as a future leader in MS research. The international prize is administered through the National MS Society and made possible by the generosity of the Charles and Margery Barancik Foundation.

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. There is currently no cure for MS. Symptoms vary from person to person and range from numbness and tingling, to mobility challenges, blindness and paralysis. An estimated 1 million people live with MS in the United States. Most people are diagnosed between the ages of 20 and 50 and it affects women three times more than men.

About the National Multiple Sclerosis Society

The National MS Society, founded in 1946, funds cutting-edge research, drives change through advocacy, and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalMSsociety.org, Facebook, Twitter, Instagram, YouTube or 1-800-344-4867.

Media Contact: Gena Hyde

gena.hyde@nmss.org 713-962-0420

Share article on social media or email:

“Salivary IgG provides epidemiologists a means of qualifying a specific population quickly and efficiently in an effort to further identify and control for disease transmission, outbreak, and distribution.”

STATE COLLEGE, Pa. (PRWEB)
January 28, 2020

Today, Salimetrics announced an addition to their trusted line of Better Salivary Assay Kits. The new Salivary Total Human IgG Assay Kit exemplifies Salimetrics’ 20+ year commitment to cutting-edge salivary bioscience research. “By measuring total immunoglobulin G in saliva, researchers can extend the accuracy and ease of use of salivary bioscience into infectious disease research and epidemiological studies,” says Supriya Gaitonde, Ph.D., Salimetrics’ Senior Applications Scientist. “Measuring salivary total IgG is a critical step for sample qualification, used to identify an individual’s immunity to specific disease targets, such as HEV, norovirus, measles, zika, EBV, and dengue, among others.” Researchers will also be able to measure total IgG against any disease specific IgG assay targets to determine an individuals’ exposure and immune response to specific immunogens.

“The launch of this Salimetrics’ Salivary IgG Assay Kit is the product of close interaction with researchers in the public health sector. Working together, the team leveraged Salimetrics’ knowledge in salivary bioscience to break through technological and biological barriers. Now, researchers can utilize a more efficient solution to problems that put populations at risk,” says Steve Granger, Ph.D., Salimetrics’ CSO. “Salivary IgG provides epidemiologists a means of qualifying a specific population quickly and efficiently in an effort to further identify and control for disease transmission, outbreak, and distribution.”

Immunoglobulin G (IgG) is a key component of the humoral immune system and regulates host immune-defense against pathogenic viruses and microbes. IgG passively diffuses into saliva through the gingival crevicular epithelium, where samples can be conveniently collected. Since IgG in saliva is bioidentical to its serum counterparts, researchers will find it an attractive alternative to blood sampling. Saliva as a non-invasive approach to monitoring immune status has the benefits of increasing participant compliance as well as the speed of sampling anywhere, anytime. “With salivary bioscience, investigators worldwide have gained knowledge through complex study designs and solved challenges that could never be feasible through traditional biological specimens,” says Dr. Gaitonde.

Research has also identified that salivary total IgG was strongly associated with salivary cytokines. A 2020 study, “Salivary total Immunoglobulin G as a surrogate marker of oral immune activity in salivary bioscience research” by Riis, et al., concluded that “Controlling for salivary total IgG may be a feasible, affordable approach to adjusting salivary biomeasure findings for the influence of the oral immune environment when it is not possible or practical to obtain clinical oral health data.” By controlling for populations at high risk of oral inflammation, studies can further improve the validity and reliability of their salivary bioscience data.

The Salimetrics Salivary Total IgG Assay Kit features a dynamic range of 0.3125 to 20 ng/mL, functional sensitivity of 0.94 µg/mL, and average inter and intra-assay coefficients of variation less than 10%. Saliva collection has been validated with SalivaBio’s passive drool protocol and follows the same convenient and reproducible methods that SalivaBio has provided the research community for years.

Salimetrics continues to be a key partner in bringing best-in-class solutions to salivary bioscience research. By using Salimetrics’ products and services, researchers can find and implement solutions where the full potential of salivary measures have yet to be realized. “With a history of supporting more than 25,000 researchers around the world, these new, high quality assays from Salimetrics will empower a new era in the application of Salivary Bioscience,” says Dr. Granger.

To learn more about the new Salivary Total Human IgG Assay Kit, researchers can visit the Salimetrics Website, or contact researcher support to integrate salivary IgG into their current or future research study.

Share article on social media or email:

Valencell logo

RALEIGH, N.C. (PRWEB)
January 27, 2020

Valencell, the leading innovator in wearable biometric sensor technology, today announced it has secured financing from strategic investors led by Halma plc, a FTSE 100 global group of life-saving technology companies, with additional participation from existing investors Sonion, TDF Ventures, GII LLC, and WSJ Joshua Fund. A representative from Halma will join the Valencell board of directors. Valencell plans to use the funds to accelerate investments in its biometric sensor systems, blood pressure technology, and sales growth.

In addition, Valencell announced the signing of a collaboration agreement with Halma plc portfolio company SunTech Medical Inc. Valencell and SunTech are cooperating on clinical-grade blood pressure solutions augmented with PPG sensor technology.

“Valencell has established a strong position in the convergence of consumer wearables and health & medical devices with advanced sensor technology to measure everything from heart rate to blood pressure,” said Kent Novak, CEO, Valencell. “With Halma leading the investment round, Valencell adds a new strategic partner with a large footprint in the health and medical sector, where Valencell is seeing great traction and opportunity. We look forward to working with our new and existing partners to expand Valencell core technology in the market.”

Valencell continues to see global demand for highly accurate biometric sensor technology with significant growth in hearables, hearing aids and other wearable devices. At CES 2020, Valencell recently launched the world’s first calibration-free blood pressure sensor system for hearables and wearables. Valencell’s technology has now been integrated into more than 50 different wearables and hearables that have come to market around the world. Valencell also has the most-cited patent portfolio in wearable PPG, which includes over 85 granted patents and more than 100 additional patents pending.

The market for wearable biometric sensors continues to rapidly expand largely driven by ear-based hearables. IDC recently said, “Hearables are the new wearables” and expects more than 273 million hearables to ship by 2023, showing 41.3% CAGR from 2019-2023. The wearables market as a whole is expected to ship nearly 500 million units by 2023.

About Valencell

Valencell transforms the science of wearable biometrics to enable impactful health outcomes. Through innovative R&D and validated technologies, we develop breakthroughs and collaborate with wearables, hearables, and medical device companies around the world to deliver amazing results. Protected by more than 85 granted patents and more than 100 patents pending, Valencell’s technology can be used in wearables and hearables for virtually anyone, anywhere, doing anything. Valencell’s biometric sensor systems are currently integrated into more wearable devices than any other technology provider in the world.

Share article on social media or email:

Dr. Assadi joins dicentra as Clinical Research Scientist and Data Specialist

“Dr. Assadi’s experience in research protocol development, statistical design and data analytics will be an extremely beneficial addition to our CRO and the clients we represent,” said Peter Wojewnik, VP of Growth, Marketing & Sales, dicentra.

TORONTO (PRWEB)
January 24, 2020

dicentra, a leading Contract Research Organization (CRO) and global consulting firm for the life sciences and food industries, is pleased to announce that Dr. Homa Assadi has joined as Clinical Research Scientist and Data Specialist, at their head office and research site in Toronto, Canada.

Dr. Assadi’s extensive experience pertains to research protocol development, statistical design, project management and research manuscript writing. This work, relating to a wide variety of emerging therapeutics, will be an asset to dicentra’s clinical team and has earned Dr. Assadi global recognition, who has presented her work at over 12 international conferences. With the recent addition of Dr. Assadi, dicentra’s clinical team will continue to provide superior CRO services to the nutraceutical industry with an unwavering focus on research integrity and data quality.

“We welcome Dr. Assadi to dicentra. Together, our team is excited for the continued growth and success of many new projects this year,” said Peter Wojewnik, VP of Growth, Marketing & Sales, dicentra. “Dr. Assadi’s experience in research protocol development, statistical design and data analytics will be an extremely beneficial addition to our CRO and the clients we represent.”

Dr. Assadi holds a Ph.D. in Biomedical Physics from the Department of Physics at Ryerson University in Toronto, Canada, an M.Sc. in Physics from Azad University in Tehran, Iran, and a B.Sc. in Physics from Esfahan University in Iran.

“I am excited to bring my unique visioning ability to dicentra. My background in research science and my experience in research development, data management, data analysis, medical and SOP writing will help to facilitate dicentra’s continued CRO growth.” said Dr. Assadi, Clinical Research Scientist and Data Specialist, dicentra. “In addition, my extensive knowledge of ICH-GCP guidelines are critical for research integrity from the outset of study design. I am thrilled to have the opportunity to bring these strengths and effective data management strategies to the clinical research team at dicentra.”

About dicentra

dicentra is a Contract Research Organization and professional consulting firm that specializes in addressing all matters related to safety, quality, and compliance for all product categories in the life sciences and food industries. We evaluate, implement, and provide all the necessary support for your products and operations, allowing you to gain market access while building confidence in your brand. We achieve this through our four business divisions: Life Sciences, Food Safety & Quality, Global Certifications, and Clinical Trials. Since our inception in 2002, we have completed over 18,000 projects and serviced over 1,200 companies internationally.

dicentra is headquartered in Toronto, Ontario and has an office in Guelph, Ontario. For more information, visit dicentra.com.

Share article on social media or email: